Black Rock Inc. Finch Therapeutics Group, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.34 - $0.56 $695 - $1,145	2,046 Added 2.85%	73,839 $28,000
Q4 2022 Feb 13, 2023	BUY	$0.36 - $56.4 $491 - $76,929	1,364 Added 1.94%	71,793 $34,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $51.3 $6,440 - $188,784	3,680 Added 5.51%	70,429 $117,000
Q2 2022 Aug 12, 2022	SELL	$1.91 - $5.11 $645,927 - $1.73 Million	-338,182 Reduced 83.52%	66,749 $189,000
Q1 2022 May 12, 2022	BUY	$5.02 - $10.47 $45,927 - $95,790	9,149 Added 2.31%	404,931 $2.04 Million
Q4 2021 Feb 10, 2022	BUY	$8.95 - $16.88 $75,564 - $142,517	8,443 Added 2.18%	395,782 $3.95 Million
Q3 2021 Nov 09, 2021	BUY	$12.2 - $16.75 $132,919 - $182,491	10,895 Added 2.89%	387,339 $5.04 Million
Q2 2021 Aug 11, 2021	BUY	$12.03 - $17.51 $4.53 Million - $6.59 Million	376,444 New	376,444 $5.3 Million

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $563M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.